口唇ヘルペス治療の世界市場：2023～2030年

口唇ヘルペスは、口唇、歯肉、または咽喉に小さな水疱ができる口唇の疾患です。これらの水疱は単純ヘルペスウイルスによって誘発されます。単純ヘルペスウイルスは典型的で非常に感染性の高いウイルスであり、米国では20歳になるまでに個人の大多数が感染します。

口唇ヘルペスの極端なケースでは、アシクロビル、ファムシクロビル、バラシクロビルなどの抗ウイルス錠剤が提案されることがあります。これらの抗ウイルス薬は、症状が最初に現れた時（例えば、口の周りにヒリヒリした痛みを感じた時）や水疱が最初にできる前に投与すれば、さらに効果があります。

市場力学：市場促進要因・市場抑制要因

有病率の増加

口唇ヘルペスの有病率の増加は、予測期間中の世界市場の成長を促進すると予想されます。例えば、ジョンズ・ホプキンスによると、米国成人の50～80％が口唇ヘルペス（HSV-1）を発症しており、口唇ヘルペスは口やその付近に冷え症や熱性水疱を生じさせる。

HSV-1またはHSV-2によって誘発される性器ヘルペスは、米国の14歳から49歳の6人に1人が罹患しています。さらに、WHOは、全世界の住民の67％近くが口唇ヘルペスまたはHSV-1を持っており、11％近くが性器ヘルペスまたはHSV-2を持っていると評価しています。また、口唇ヘルペスの原因である単純ヘルペスウイルス1型は、全世界で37億人に感染していると考えられています。

さらに、研究活動の増加、認知度の向上、市場開拓も、予測期間中の世界の口唇ヘルペス市場の成長に貢献すると期待されています。

厳しい規制当局

FDAやEMAなど、新薬の承認や商業化を管理する厳しい規制当局の存在は、予測期間中の世界市場の成長を妨げると予想されます。さらに、治療の選択肢の少なさ、低投資、低資金、高薬品開発コストも、予測期間中の世界市場成長の妨げになると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 普及の拡大
  • 抑制要因
    • 厳しい規制当局
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 償還分析
• 特許分析
• パイプライン分析
• 疫学分析
• SWOT分析
• DMIオピニオン

第6章 COVID-19分析

第7章 薬剤別

• アシクロビル
• バラシクロビル
• ファムシクロビル
• ドコサノール
• その他

第8章 投与経路別

• 局所
• 経口
• その他

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他のアジア太平洋
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• Teva Pharmaceuticals Industries Ltd
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Carlsbad Tech
• Novartis AG
• Innocutis Holdings, LLC
• Fresenius Kabi AG, Inc.
• Apotex Inc.
• Mylan N.V.
• AbbVie Inc.
• GSK plc
• Viatris Inc.

第13章 付録

Overview

Herpes labialis or oral herpes is a condition of the mouth region that generates little, sore blisters to grow on the lips, gums, or throat. These blisters are induced by the herpes simplex virus, a typical and highly transmissible virus that contaminates a majority of individuals in the U.S. by the time they attain the age of 20.

For extreme cases of herpes labialis, antiviral tablets may be suggested including acyclovir, famciclovir, and valacyclovir. These antiviral drugs are additionally efficacious if they are dosed as shortly as manifestation first presents (e.g. when tingling is felt around the mouth) and before the blisters first occur.

Market Dynamics: Drivers & Restraints

Growing Prevalence

The growing prevalence of Herpes Labialis is expected to boost the global market growth during the forecast period. For instance, according to Johns Hopkins Fifty to eighty percent of American adults hold oral herpes (HSV-1), which generates cold sores or fever blisters in or near the mouth.

Genital herpes, induced by HSV-1 or HSV-2, influences one among six individuals in the U.S. aged 14 to 49. Moreover, the WHO assesses that nearly 67% of the globe's inhabitants contain oral herpes or HSV-1 and that almost 11% have genital herpes, or HSV-2. Also, the herpes simplex virus type 1, which is the highly dominant reason for herpes labialis, is considered to be current in 3.7 billion individuals globally.

Furthermore, the increasing research activities, growing awareness and market developments are also expected to contribute to the global Herpes Labialis market growth during the forecast period.

Stringent Regulatory Authorities

The presence of stringent regulatory authorities controlling new drug approvals and commercialization including the FDA and EMA among other is expected to hamper the global market growth during the forecast period. Furthermore, the low treatment choices, low investments, fundings and high drug development costs are also expected to hamper the global market growth during the forecast period.

Segment Analysis

The global herpes labialis treatment market is segmented based on drug, route of administration, distribution channel and region.

Acyclovir is Expected to Dominate Market

Owing to the increasing product introductions and approvals for Acyclovir is expected to boost the segment market growth, dominating the global market during the forecast period. For instance, in October 2022, Camber Pharmaceuticals introduced Acyclovir Oral Suspension and extended its current portfolio. Acyclovir Oral Suspension is an artificial nucleoside analog functional in herpes virus treatment. Moreover, in November 2020, Amneal Pharmaceuticals, Inc. obtained authorization for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Acyclovir Cream, 5%. Acyclovir Cream, 5%, is the generic version of Zovirax to treat recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older.

Geographical Analysis

North America is Expected to Dominate the Global Market

Owing to the increase in product approvals and clinical investigations for herpes labialis treatment in North America, the region is expected to dominate the global market throughout the forecast period. For instance, in December 2020, EPI Health, LLC obtained an FDA New Drug Application (NDA) authorization for Sitavig (acyclovir) Buccal Tablet for the treatment of recurrent herpes labialis in immunocompetent individuals.

Moreover, Bayer has begun a Phase 3 randomized, Multi-Center, Double-Blinded, Self-Initiated, Treatment Study Comparing Sitavig (Acyclovir) 50 mg Mucoadhesive Buccal Tablet to Placebo in the treatment of herpes labialis in immunocompetent adults in United States. Furthermore, the growing prevalence and awareness in this region is also boosting the regional market growth during the forecast period.

Market Segmentation

By Drug

• Acyclovir
• Valacyclovir
• Famciclovir
• Docosanol
• Others

By Route of Administration

• Topical
• Oral
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• In August 2021, the Xerese (acyclovir and hydrocortisone) cream (recommended for the treatment of recurrent herpes labialis (cold sores) in adults) obtained FDA authorization for a new drug application.
• In February 2021, FDA had received the Abbreviated New Drug Application (ANDA) from Innocutis Holdings, LLC for its Acyclovir Cream 5% to treat herpes labialis.
• In October 2020, Maruho Co., Ltd. Reported promising conclusions a phase 3 clinical investigation of its topical medication, MRK-003, fto treat recurrent herpes labialis.

Competitive Landscape

The major global players in the market include: Teva Pharmaceuticals Industries Ltd, Carlsbad Tech, Novartis AG, Innocutis Holdings, LLC, Fresenius Kabi AG, Apotex Inc., GSK plc, Abbvie Inc., and Mylan N.V. among others.

Why Purchase the Report?

• To visualize the global herpes labialis treatment market segmentation based on drug, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of herpes labialis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global herpes labialis treatment market report would provide approximately 61 tables, 69 figures and 186 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Growing Prevalence
  • 4.1.2. Restraints
    • 4.1.2.1. Stringent Regulatory Authorities
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. Pipeline Analysis
• 5.8. Epidemiology
• 5.9. SWOT Analysis
• 5.10. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Drug

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
  • 7.1.2. Market Attractiveness Index, By Drug
• 7.2. Acyclovir*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Valacyclovir
• 7.4. Famciclovir
• 7.5. Docosanol
• 7.6. Others

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Topical*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Oral
• 8.4. Other

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Teva Pharmaceuticals Industries Ltd*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Carlsbad Tech
• 12.3. Novartis AG
• 12.4. Innocutis Holdings, LLC
• 12.5. Fresenius Kabi AG, Inc.
• 12.6. Apotex Inc.
• 12.7. Mylan N.V.
• 12.8. AbbVie Inc.
• 12.9. GSK plc
• 12.10. Viatris Inc.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us